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Abstract
Background: Pulmonary hypertension (PH) is common, dangerous and has multiple
causes. Vasodilator therapy has significantly improved the prognosis of patients with
pulmonary arterial hypertension (PAH), but the diagnosis can be challenging, requiring
right heart catheterisation (RHC). Differentiating pre-capillary PH (prePH) and postcapillary PH (postPH) and measuring pulmonary vascular resistance (PVR) are key steps
for diagnosing PAH. A novel echocardiographic parameter, the pulmonary to left atrial
ratio (ePLAR), which is derived from the tricuspid regurgitation velocity (TRV) divided
by the ratio between the early diastolic filling velocity and the early mitral annulus
velocity (E/e’), i.e., ePLAR=TRV/E/e’, has been described as a surrogate for RHC. This
retrospective cohort study tests the ability of ePLAR to differentiate prePH and postPH,
in a large real world database.
Methods: The data from all RHC performed within a 5-year period (January 2010 to
February 2015) were extracted from the hospital database. The closest corresponding
echocardiograms (echos) were searched in the national echo database Australia (NEDA)
using the identifiers from RHC data. The performance of ePLAR in differentiating two
PH physiologies was compared against the gold standard RHC using various statistical
methods.
Results: 887 pairs of echos and RHCs were merged and analysed in our study. The
median time difference between RHC and echocardiography was 7 (IQR 1-62) days.
The ePLAR was calculable in 184 cases (21%). Median (IQR) ePLAR values were
significantly different between prePH and postPH groups: 0.35 (0.13-0.50) m/s vs 0.17
(0.12-0.23) m/s (P=0.003), despite both groups having similar mean pulmonary artery
pressures. The optimal ePLAR cut-off of 0.28m/s had a positive predictive value of 94%
for postPH, with sensitivity of 83% and specificity of 67%.
Conclusions: ePLAR helps to discriminate postPH from prePH and may be useful in
evaluating these patients.
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Chapter 1. Introduction
1.1. Background
Pulmonary Hypertension (PH) is a condition where there is an abnormally high blood
pressure in the pulmonary arterial system. PH can be caused by multiple pathologies
ranging from genetics, left heart diseases, lung diseases, toxins, infections to
thromboembolic diseases (1). The prognosis and treatment vary greatly depending on
the underlying aetiology. Regardless of the underlying pathology, PH can lead to
debilitating symptoms and untimely death if left untreated. The true prevalence of PH is
poorly understood: however, emerging evidence suggested that it was under-reported
previously (2, 3).
Although RHC is the current gold standard for confirming the diagnosis,
echocardiography (echo) usually provides first objective evidence of PH. Differentiating
pre- and post-capillary PH and measurement of pulmonary vascular resistance (PVR) are
the key steps in evaluation of PH patients and currently the RHC is necessary. The
advanced therapy or pulmonary vasodilator therapy is costly and only beneficial for
patients with PH who have increased PVR. To prescribe PBS (Pharmaceutical Benefit
Scheme) subsidised advanced PH therapy in Australia, it is necessary to prove low left
atrial pressure represented by pulmonary capillary wedge pressure (PCWP) and elevated
PVR by RHC. Unless a patient is being assessed for the heart transplant, group 2 PH
patients will not benefit from routine RHC which has rare but potential serious risks. It
is also now well known that PH due to left heart disease (PH-LHD) or Group 2 PH is the
commonest form of PH(4, 5). With the increasing prevalence of all forms of PH, a
reliable non-invasive surrogate to RHC is urgently needed to better evaluate the patients.
This will lead to overall improvement in outcomes of PH patients by earlier detection of
PH, avoidance of unnecessary procedures and more appropriate use of resources.
In this study, we investigated the performance the echocardiographic pulmonary to left
atrial ratio (ePLAR) in differentiating the two major physiologies of PH as a surrogate to
invasive haemodynamic parameters obtained with RHC. The chapter 2 of this thesis
details the literature review on pathophysiology of different type of PH and various non-
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invasive surrogate of PVR. The chapter 3 describes the original research work done at
Royal Perth Hospital to investigate the ePLAR in differentiating pre-vs post-capillary
PH.

1.2. Study Objectives
Primary Objective
In the setting of pulmonary hypertension, to measure the accuracy of ePLAR
(Echocardiographic Pulmonary Artery to Left Atrial Ratio) to differentiate the two major
PH physiologies, i.e., pre-and post-capillary PH.
Secondary Objectives
1. To identify other potential echocardiographic markers useful for identifying
abnormal pulmonary vascular resistance (PVR) and transpulmonary gradients
(TPG) in pulmonary hypertension.
2. To better understand the haemodynamic changes in patients with pulmonary
hypertension caused by different pathologies.
3. To identify echocardiographic markers of increased left heart pressure in PH to
facilitate diagnosis of PH-LHD
1.3. Hypotheses
Primary Hypothesis:
In the setting of pulmonary hypertension, ePLAR measurement is an accurate method of
differentiating pre-and post-capillary PH
Secondary Hypothesis:
ePLAR is superior to previously published methods of estimating PVR.
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Chapter 2. Literature Review (Paper 1)
Non-invasive Assessment of Pulmonary Vascular Resistance in Pulmonary
Hypertension: Current Knowledge and Future Direction
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Mount Hospital, Perth, Western Australia
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Prince Charles Hospital, Queensland
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Abstract
Pulmonary Hypertension (PHT) is relatively common, dangerous and under-recognised.
PHT is not a diagnosis in itself; it is caused by a number of differing diseases each with
different treatments and prognoses. Therefore, timely and accurate recognition of the
underlying cause for PHT is essential for appropriate management. This is especially
true for patients with Pulmonary Arterial Hypertension (PAH) in the current era of
disease-specific drug therapy.
Measurement of Pulmonary Vascular Resistance (PVR) helps separate pre-capillary
from post-capillary PHT, and is measured with right heart catheterisation (RHC).
Echocardiography has been used to derive a number of non-invasive surrogates for PVR,
with varying accuracy. Ultimately, the goal of non-invasive assessment of PVR is to
separate PHT due to left heart disease from PHT due to increased PVR, to help
streamline investigation and subsequent treatment.
In this review, we summarise the physiology and pathophysiology of pulmonary blood
flow, the various causes of pulmonary hypertension, and non-invasive surrogates for
PVR.

Keywords: Pulmonary Hypertension (PHT); Doppler Echocardiography; Pulmonary
Arterial Hypertension; Pulmonary Vascular Resistance (PVR); Heart Failure with
Preserved Ejection Fraction (HFpEF)
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Introduction
Pulmonary Hypertension (PHT), defined by a mean pulmonary artery pressure at or
above 25mmHg, can be broadly differentiated physiologically into pulmonary arterial
hypertension (PAH) due to increased Pulmonary Vascular Resistance (PVR), PHT due
to increased pulmonary venous pressure but with a normal PVR (usually due to left heart
disease), or a combination of both abnormalities. This differentiation is a crucial step in
the investigation of patients with PHT, since the treatment of PHT due to left heart
disease is fundamentally different from PHT due to abnormally increased pulmonary
vascular resistance. Simply identifying the presence of PHT is necessary but not
sufficient to manage such patients, and measurement of PVR is a key step. However,
assessment of PVR usually requires right heart catheterisation (RHC), which is invasive,
has potential complications, and therefore not universally performed in the investigation
of PHT.
Pulmonary hypertension is relatively common and associated with a high risk of
death(1), yet often goes unrecognised for extended periods. Regardless of aetiology, the
common consequence of all forms of untreated PHT is symptomatic breathlessness,
progressive right ventricular failure and ultimately death. With the development of
effective advanced therapy for PAH, there is a need for simple non-invasive tools that
can estimate PVR and help identify patients who would benefit from more
comprehensive investigation, including right heart catheterisation. In this review, we
will review and summarise the biochemical compounds and mechanical variables that
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affect blood flow through the pulmonary vasculature. We will also summarise
techniques that have been used to non-invasively estimate PVR.

Physiology of pulmonary blood flow and pulmonary vascular resistance (PVR)
Normal pulmonary circulation is low-pressure, low-resistance and highly dynamic,
which allows major increases in pulmonary blood flow in response to exercise with only
small increases in pressure. Pulmonary arterial blood flow regulation is maintained by
pulmonary vascular resistance and recruitment of additional pulmonary capillaries,
without the option of diversion through different vascular beds. This differs markedly
from the systemic circulation, in which exercise results in hyperaemia in skeletal
muscles, flow-mediated dilatation of conduit arteries, and dynamic changes in peripheral
vascular resistance for each relevant vascular bed.
The degree of pulmonary arterial tone, via smooth muscle contraction, is governed by a
series of vasoactive compounds released by the pulmonary vascular endothelium.
Patients with PAH

have increased level of compounds that are responsible for

vasoconstriction, thrombosis and smooth muscle cell hyperplasia (2-4). Each of the
compounds exerts different effects on vascular smooth muscle, endothelial cell,
surrounding blood cell responses. These responses are summarised in Table 1.
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Table 1: Vasoactive compounds affecting pulmonary vascular resistance and drugs for
PHT targeting those compounds
Compounds

Effects

Therapeutic agents modulating
these compounds

Thromboxane A2

Vasoconstrictor, stimulator of

(TxA2)

platelet aggregation and

None

proliferation
Prostacyclin

Vasodilator, inhibitor of platelet

Epoprostenol, Iloprost

aggregation and has
antiproliferative property
(counteracts thromboxane A2)
Endothelin-1

Potent vasoconstrictor and

Endothelin receptor antagonists

(ET-1)

stimulator of pulmonary artery

(e.g. bosentan, macitentan)

smooth muscle cells
proliferation
Nitric Oxide

Vasodilator and inhibitor of

Inhaled NO

(NO)

platelet activation and vascular

Phosphodiesterase inhibitors

smooth-muscle cell proliferation,

(e.g. Sildenafil) reduced the

counteracts endothelin-1’s

inactivation of cyclic guanosine

actions

monophosphate through which
NO mediates its effects

Serotonin

Vasoconstrictor

No therapeutic agent available
currently
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Pulmonary blood flow is further regulated via capillary recruitment. In states of resting
cardiac output, a number of capillary beds are in a collapsed state having neither blood
perfusion nor ventilation. As the CO increases, there is an increase in the capillary blood
volume resulting in recruitment of these distensible capillary beds without an increase in
PVR.
Despite the responsive nature of this system, many additional factors affect pressure
through the pulmonary vasculature. The Hagen-Poiseuille equation below describes the
relationship between pressure, flow, viscosity and radius in a hollow, straight, nondistensible tube (5).

= pressure change
= length of pipe
= dynamic viscosity
= volumetric flow rate
= radius
The change in pressure across the pulmonary artery is inversely proportional to the
fourth power of the radius. If the radius of the pulmonary artery decreases (e.g. due to
smooth muscle hypertrophy, hypoxic vasoconstriction or pulmonary thromboembolic
disease), there is an accompanying disproportionate increase in the pressure across the
pulmonary artery, and a higher up-stream pressure will be required in order to maintain
normal down-stream pressures.
There are additional effects on pulmonary pressures from blood viscosity (e.g.
hyperviscosity syndromes increase pulmonary pressures whereas anaemia decreases
pulmonary pressures or increased blood flow rates (high cardiac output or valvular
disease).
15

Finally, the dynamics of blood flow in the left heart affect pulmonary blood flow. In a
normal heart, left ventricular relaxation during diastole is an active (ATP dependent)
process, causing a rapid fall in ventricular pressure and a “suction” effect on left atrial
blood. This results in relative emptying of pulmonary vein blood into the left atrium, and
a fall in pulmonary capillary pressure. Further, during ventricular systole, the downward
motion of the mitral valve toward the ventricular apex elongates the left atrium creating
a systolic “suction” effect on pulmonary vein blood. Simultaneous right ventricular
systolic contraction ensures a constant supply of blood into this low pressure circuit with
rapid pulmonary capillary transit. These events cause efficient systolic and diastolic
pulmonary capillary blood transit. Conditions that decrease left ventricular and left atrial
compliance such as chronic atrial fibrillation, the stiff left atrial syndrome(6, 7), left
ventricular hypertrophy and restrictive cardiomyopathy(8), disrupt the finely balanced
transit through the pulmonary circulation and increase pulmonary capillary pressures.

Measurement of pulmonary vascular resistance (PVR)
In humans in vivo, pulmonary haemodynamics are most accurately measured invasively
using right heart catheterisation (RHC). The mean pulmonary artery pressure (mPAP)
can be measured by averaging the pressure inside the pulmonary artery throughout the
cardiac cycle. To measure the pulmonary capillary wedge pressure (PCWP), the catheter
is advanced into a branch pulmonary artery, and a small balloon attached near the tip of
the catheter is inflated until the pulmonary artery is occluded. The mean pressure
measured at the tip of the catheter is taken to be the back-pressure from the left heart,
and approximates the left atrial pressure in the absence of pulmonary vein stenosis. A
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mean PCWP <15mmHg is generally accepted to indicate normal left atrial mean
pressure, and is required to diagnose PAH, excluding PHT due to left heart disease(9).
The PVR is the resistance generated by the pulmonary vasculature against which the
blood must travel from right to left side of the heart and is influenced by the
transpulmonary gradient and the cardiac output:
PVR = TPG/CO
TPG = mPAP-PCWP
TPG – Transpulmonary gradient
mPAP – mean Pulmonary Artery Pressure in mmHg
PCWP – Pulmonary Capillary Wedge Pressure in mmHg
CO – Cardiac Output in L/min

In general, the higher the TPG and/or the lower the CO, the higher the PVR. PVR is
preferred to TPG, since it takes blood flow into account (10). The equivalent measure in
the systemic circulation, the systemic vascular resistance (SVR), is generated by a
number of different systemic arterial vascular beds and is approximately 10 fold higher
than the PVR. A normal PVR is 1-3mmHg.min/L, and decreases further with exercise
and increased CO. For convenience, the mmHg.min/L units are often dropped and
presented as Wood Units (WU), in honour of Earl Wood, an early pioneer in the field.
Despite its importance in PHT diagnosis and management, RHC has a number of
drawbacks. It is invasive with potential serious risks such as ventricular arrhythmias,
thromboembolism, myocardial or valvular injury, pulmonary infarction and rupture of a
pulmonary artery. RHC requires significant skills and standardisation of the procedure,
and is not universally available. Although RHC accurately measures the PCWP, it may
17

not reflect the true left ventricular filling pressure (11, 12), particularly if mitral stenosis
(13), pulmonary vein stenosis or a noncompliant left atrium (6) is present.

Clinical Classification and Epidemiology of Pulmonary Hypertension
PHT is defined as an increased resting mPAP at or above 25mmHg, measured with RHC
(9). PHT is not a disease in itself, but simply a marker of a pathophysiological
abnormality that requires explanation. A clinical classification of PHT has been
provided by the World Health Organisation (WHO) with several more recent updates
(14). The Latest Classification (NICE 2013) classified PHT into 5 groups, summarised
in Table 2.
Table 2: NICE classification of pulmonary hypertension, with abridged examples for
each group.
Pulmonary Hypertension Group
Group 1
Pulmonary Arterial Hypertension
Group 2
PHT due to Left Heart Disease
Group 3
PHT due to Lung Disease

Examples
Idiopathic PAH
PAH associated with other diseases:
Scleroderma
Congenital heart disease
Myocardial disorders:
Valvular heart disease
Congenital LV inflow or outflow obstruction
COPD and Interstitial lung disease
Sleep disorders
Chronic hypoxia

Group 4
Chronic
Pulmonary Multiple chronic pulmonary emboli
Thromboembolic Disease (CTEPH)
Group 5
Haematologic disorders
PHT with multifactorial cause
Chronic renal failure
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The data from recent studies suggest the true prevalence of PHT in general population is
higher than previously reported (15-17). We have previously reported a minimum
‘indicative’ prevalence for all forms of PHT at 326 cases/100 000 inhabitants of
Armadale and its surrounding area in Western Australia. Left heart disease-associated
PHT was the commonest cause (250 cases/100 000) and had the worst prognosis. Patient
with PAH who were treated with disease specific therapy had the best prognosis (18).
Moreover, there is significant delay between symptom onset and the time of diagnosis
leading to poor prognoses for patients ( 19, 20).
Previously, patients with group 1 PHT (PAH) had worse survival than other groups. The
era of advanced therapy has improved the overall prognosis of PAH patients (21) with
some trials suggesting one-year survival rates of 84 percent (22). Advanced therapy
includes specific pulmonary vasodilator drugs, such as Prostacyclin, endothelin receptor
antagonists (ERAs) and phosophodiesterase type-5 (PDE-5) inhibitors. These decrease
the rate of progression and complications as well as improve symptoms associated with
PAH, with the greatest benefits derived from early commencement of therapy.

A Proposed Pathophysiological Classification of PHT based on PVR
The latest clinical classification for pulmonary hypertension only partially reflects the
underlying pathophysiology of each disease. For this reason, there is overlap in
treatment between groups. An alternative method of classification is to describe the
pathophysiology underpinning the PHT. Using this method, the causes of PHT can be
subdivided into two major groups: pre-capillary or post-capillary based on whether the
pulmonary vascular resistance is normal or increased. Pre-capillary PHT is defined by a
high transpulmonary gradient of at least 12mmHg, a high pulmonary vascular resistance
19

of >3 WU and pulmonary capillary wedge pressures of <15mmHg (normal left heart
filling pressure). These “high PVR” pulmonary hypertension patients may respond to
pulmonary vasodilator therapy, and would include individuals with Group 1 or Group 3
PHT. Some patients from groups 4 or 5 may also be included, depending on their PVR.
Post-capillary pulmonary hypertension, or “normal PVR” pulmonary hypertension, is
characterised by an increased PCWP of >15mmHg but normal or low PVR(9, 10). These
patients are predominantly Group 2 (left heart disease).
Some patients have a mixed picture, with PCWP due to elevated LV filling pressures,
but with coexisting increased PVR. These individuals have a disproportionate rise in
their pulmonary artery pressure beyond that expected from the degree of left heart
disease alone. Such patients may respond only partially to diuretic therapy and treatment
of their left heart disease, however the use of pulmonary vasodilator therapy in this
situation is controversial(23-26).
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The range of abnormalities are summarised in Figure 1 below.

A

B

C

D

Figure 1: The range of abnormalities in PHT. Panel A shows a normal scenario with
normal PVR and normal LV filling pressures. Panel B shows normal LV filling
pressures but increased PVR resulting in PAH. Panel C demonstrates increased LV
filling pressures with normal PVR, resulting in pulmonary hypertension due to left heart
disease. Panel D shows a mixed picture, with increased LV filling pressure but a
disproportionate increase in pulmonary artery pressure caused by increased PVR. PVR =
Pulmonary Vascular Resistance; RVSP= right ventricular systolic pressure; LV= left
ventricle.
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Identifying increased PVR and/or abnormal left heart filling pressure helps guide
therapy, particularly in the era of advanced therapies which target the pulmonary
vasculature (27-32). Heart Failure with Preserved Ejection Fraction (HFpEF) causing
PHT due to increased filling pressures should not be misclassified as PAH (33),
particularly since some pulmonary vasodilator therapy in this group of patients may be
harmful.

Echocardiography in Pulmonary Hypertension
Echocardiography (echo) is the most commonly used noninvasive tool for identifying
PHT, and is particularly useful when screening for PHT (34). Using the velocity of
tricuspid regurgitation (TRV), pulmonary artery systolic pressure (PASP) can be
estimated (35-37) (Figure 2). There is a strong association between the pulmonary artery
pressure (PAP) measured by right heart catheterization and that obtained by echo (18,
38).
PASP = RAP + 4(TRV)2
Figure 2. From Apical 4 chamber view, the Tricuspid Regurgitation Velocity (TRV) is
measured by using continuous wave Doppler. The pulmonary artery systolic pressure
(PASP) is estimated using the modified Bernoulli equation (∆P=4V2). P=change in
pressure, V=velocity of flow(36).

Pulmonary Vascular Resistance estimation with echocardiography
A number of echocardiographic markers have been proposed for the noninvasive
estimation of PVR(39-42). However, many of these markers cannot reliably separate
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PHT due to left heart disease from PHT due to increased PVR. Currently, there is no
single reliable method of estimating PVR non-invasively that has been tested and proven
in a large-scale study.
As early as 1975, researchers have described methods to estimate PVR non-invasively.
In a study by Hirschfeld et al. (39), 64 patients with congenital heart disease underwent
RHCs and echo examinations. 57 patients had both examinations on the same day and 4
patients had them within one month; however, 3 patients’ echoes were done 3-5 years
after RHC. The ratio of right ventricular ejection time (RVET) to right ventricular preejection period (RPEP) was found to correlate well with invasive measurements of
pulmonary artery diastolic pressure (PADP), PVR and mPAP. The correlation
coefficient of the proposed index with PVR was 0.69. The study was limited to patients
with congenital heart diseases and extrapolation to PHT patients due to other etiologies
may not be appropriate. Dabestani et al. examined the pulmonary artery flow velocities
by Pulsed Doppler echocardiography in 39 patients and found a negative linear
correlation between Pulmonary Artery acceleration time and total pulmonary
resistance(43).
Scapellato, and colleagues simultaneously performed Doppler echocardiographic and
RHC measurements in 63 patients with sinus rhythm and severe heart failure(40).
Doppler measurements from pulmonary flow and TRV curve were correlated with
invasive PVR. Among the investigated variables, the acceleration time of pulmonary
systolic flow was found to have best correlation with the invasive PVR (r=-0.68). The
correlation coefficient improved to 0.96 by using the equation:
PVR= -0.156+1.154*[(PEP/AcT) /TT]
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PEP = Pre-ejection period
AcT=Pulmonary acceleration time
TT= total systolic time
The principal advantages of this study were simultaneous measurement of both echo and
RHC, and the relative simplicity and accuracy of their equation up to 9 WU. However,
the study was small and excluded patients with atrial fibrillation and those without heart
failure.
The formula described by Abbas et al. in 2003 is commonly used in echo laboratories as
a noninvasive PVR assessment. They performed simultaneous echo and RHC in 44
patients (41). They found a close association (r=0.93, CI 0.87-0.96) between the
invasively measured PVR and the ratio of the TRV to the velocity time integral of the
flow through the right ventricular outflow tract (TVIRVOT,). Their equation approximated
to the following:
PVRECHO =0.16 +10 x TRV/TVIRVOT
This method is easy to calculate from standard echo measurements, but the study was
relatively small, did not include patients with PVR over 6WU, and did not account for
left atrial pressure, an essential component of the invasively measured PVR. In
subsequent analyses, the original Abbas equation was shown to underestimate invasive
PVR assessment in those with PVR over 6WU(44), which could be partly corrected by
incorporating assessment of LV filling pressures into the equation (using E:E’ ratios).
The E:E’ ratio is calculated as the ratio of the early diastolic flow through the mitral
valve (measured using pulsed wave Doppler echo) to the early diastolic descent velocity
of the medial mitral annulus (measured using pulsed wave tissue Doppler velocities).
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The E:E’ ratio is commonly used as a surrogate for left ventricular filling pressure (4547) and predicts mortality in left heart disease(48-50). Using data from five separate
studies, Abbas et al. demonstrated a more robust association between PVR and
TRV2/TVIRVOT (42), including patients with a PVR > 6WU. The ratio has been further
validated by a similar study in post-cardiac surgery patients in an intensive care setting
(51).
A further study by Haddad et al. in 2009 demonstrated that invasively measured PVR
correlated well with the index of PASP to the heart rate (HR) times the TVIRVOT
[PASP/(HR x TVIRVOT)] in 51 patients with established PAH (52). This method is also
simple to use and the measurements required for the equation are routinely performed in
most echocardiography laboratories. Small number of participants again limited this
study. Additional sources of error include the need to estimate the right atrial pressure in
their equation.

Table 3: Summary of echocardiographic methods for estimating PVR
Investigators and

Surrogate Indexes/Formulae

References

Number Correlation
of

coefficient (r) of

patients

surrogate index with
PVR

Hirschfeld et al.

RVET/ RPEP

(39)

(RVET= right ventricular ejection

64

0.69

time,
RPEP =right pre-ejection period.)
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Scapellato et al.

PVR=0.156+1.154*[(PEP/AcT) /TT]

(40)

(PEP=Pre-ejection period,

63

0.96

AcT=Acceleration time,
TT=total systolic time of pulmonary
flow.)
Abbas et al.

TRV/TVIRVOT

(original) (41)

(VTR= Tricuspid Regurgitation

44

0.929 (95%
confidence interval
0.87 to 0.96)

Velocity,
TVIRVOT=Time Velocity Integral of
the flow through the right ventricular
outflow tract)
Abbas et al.

TRV/TVIRVOT (original)

150

0.76

(Analysis of raw

TRV2/TVIRVOT (modified)

patients

0.79

data from 5

on final

validation

analysis

studies)(42)
Haddad et al. (50)

PASP/(HR x TVIRVOT)

51

0.860 (95%
confidence interval,
0.759-0.920)

Recently, a new echocardiographic method for estimating transpulmonary gradients has
been proposed by Scalia et al (53). The ePLAR, or echocardiographic pulmonary to left
atrial ratio is the ratio of peak tricuspid regurgitation velocity (a marker of pulmonary
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artery systolic pressure) and E:E’ ratio (a marker of left ventricular filling pressure).

ePLAR =

TRV
E: E′

ePLAR = Echocardiographic Pulmonary to Left Atrial Ratio
TRV = Tricuspid Regurgitation Velocity
E: E′ = the ratio of transmitral E-wave to septal mitral annular Doppler Tissue Imaging

E'-wave
The marker is simple, non-invasive, and uses measurements performed as part of a
standard echocardiogram. For 16,356 “normal” echocardiograms without PHT, the mean
ePLAR was 0.30 +/- 0.09m/s. For 133 patients with PHT, the ePLAR helped separate
those with elevated PVR from those with PHT due to left heart disease: In 35 patients
with pre-capillary PHT confirmed using RHC (with elevated PVR, mean 6.5+/-3.6WU),
the mean ePLAR was 0.44 +/- 0.22 m/s. The ePLAR was significantly lower (0.18 +/0.18m/s) in those with PHT due entirely to left heart disease (81 patients, mean PVR
3.1+/-2.7WU). The major limitation of the study is non-simultaneous performance of
echocardiograms and RHC. Although helpful to identify patients with elevated
transpulmonary gradients, ePLAR does not take cardiac output into account.

Conclusions
PHT is common and associated with significant mortality. A rigorous approach to its
diagnosis is required by every echo laboratory, starting with estimation of pulmonary
artery pressure. PHT is not a diagnosis in itself, and identification of the underlying
cause will determine approaches to treatment. Estimation of PVR is an important aspect
of the diagnostic workup and a number of non-invasive methods for PVR measurement
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have been proposed. Like their invasive counterparts, most non-invasive methods rely
on a combination of pulmonary artery pressure and flow assessment; however, most
studies describing these methods suffer from small sample study size, limited reliability
across a broad range of patients, and do not take left atrial pressure into account. New
methods such as ePLAR show promise, but require further study in large cohorts with
differing forms of pulmonary hypertension.
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The literature review in the above paper highlights that there is a need for a noninvasive marker that can reliably differentiate two important PH physiologies, namely
pre-capillary PH and post-capillary PH. Studies to date have been limited by small
sample sizes with largest study being a meta-analysis with total of 150 patients. Instead
of developing a surrogate echocardiographic marker of specific invasive measurement
such as PVR, I believe developing a method of differentiating the two PH physiologies
will be more useful in clinical practice. The new method should be a screening tool that
can reliably identify patients who require further invasive assessment. Therefore, it
should be tested in a real-world setting with large number of participants.
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1. Introduction

Pulmonary hypertension (PH) is defined by mean pulmonary artery pressure (mPAP) ≥
25mmHg at rest (1, 6). It is a potentially fatal, debilitating pathology with poorly
understood epidemiology (2, 7-9). The clinical classification of PH consists of 5
different groups (10) according to the underlying pathophysiology (10, 11).
Management and prognoses of PH patients vary greatly depending on the underlying
aetiology. The majority of PH is secondary to left heart diseases (2, 12, 13) and these
patients need to be differentiated from patients with pulmonary arterial hypertension,
who will benefit from modern vasodilator therapy. Right heart catheterization (RHC)
can provide useful haemodynamic parameters to differentiate the underlying
pathologies. However, RHC is not readily available, is operator dependent, and can be
associated with potentially serious risks.

Because of the complexity in diagnosis and the low level of awareness, PAH patients are
often misdiagnosed or the diagnosis is significantly delayed, leading to a worse
prognosis (14, 15). The symptoms of early PAH may be subtle and non-specific. The
first objective evidence of PH is usually provided by Doppler echocardiography.
Pulmonary artery systolic pressure (PASP) can be estimated by applying modified
Bernoulli equation to the maximal tricuspid regurgitation velocity (TRV) and adding the
assumed right atrial pressure (16). A PASP of over 40mmHg is commonly used as the
echocardiographic cut-off to define PH but this is non-specific and does not localise the
site or mechanism of the problem. Although the former can usually be defined by RHC,
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it is not feasible or appropriate for all patients with elevated estimated PASP by echo to
undergo invasive investigation.

Haemodynamically, PH can be classified into pre-capillary PH (prePH) and postcapillary PH (postPH) based on the pulmonary capillary wedge pressure (PCWP)
obtained by RHC (1, 6). Patients with prePH have pulmonary vascular disease
manifesting as a normal PCWP (≤15mmHg) and a high pulmonary vascular resistance
(PVR) (>3 Wood units, WU) (6). PostPH is characterised by a high PCWP (>15mmHg),
usually caused by increased left heart filling pressure (e.g. systolic or diastolic heart
failure). Within the PostPH group, some patients develop pulmonary vascular disease,
resulting in a high PVR, causing an out-of-proportion rise in the PAP (PVR>3WU).
Therefore, a complex picture may emerge requiring measurement of the PAP, PVR and
PCWP (1, 6).

The original formula for PVRecho (TRV/TVIRVOT x 10) was described by Abbas et al. in
a study involving 44 patients (17) who had simultaneous echos and RHC. The original
formula provided correlation coefficient (r) of 0.929 in the original study. However, the
formula was revised to TRV2/TVIRVOT x 5 in 2013 after the meta-analysis on the data of
150 patients from five validation studies. The revised formula had better correlation than
the original formula (r=0.79 vs 0.76) to invasively measured PVR, when applied to the
meta-analysis data of 150 patients (18).

The ePLAR was recently proposed as a surrogate echo marker of TPG and as a noninvasive marker of PVR in patients with PH (19). The ePLAR is a simple ratio of the
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maximal velocity of tricuspid regurgitation (TRV) and the ratio of early mitral filling
velocity and the mitral annular velocity (E/e’), thus the ePLAR=TRV/(E/e’). TRV is
routinely used to estimate pulmonary artery systolic pressure (PASP) (16) and mitral
E/e’ is a validated marker of left atrial pressure (20-22).

2. Study Objectives

We aimed to investigate the ability of the ePLAR (19), to differentiate between prePH
and postPH, in a real-world database containing RHCs and echos. We also aimed to test
the performance of ePLAR against the previously published PVRecho by Abbas at el. (17,
18, 23).

3. Methods

A retrospective cohort study was conducted at the Royal Perth Hospital, a referral centre
for PH patients. Human Research Ethics Committee approvals from both the University
of Notre Dame and Royal Perth Hospital were obtained. The data from all RHCs
performed for various indications, between January 2010 and February 2015 was
automatically extracted from the hospital database (AXIOM Sensis XP information
system, version VC11D). The echos of patients in the RHC database were then extracted
from the National Echo Database Australia (NEDA). The closest corresponding echo
and RHC was extracted and the two databases were merged. Data analysis was
performed using IBM SPSS Statistics software version 24.
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The cases with calculable ePLAR were categorised into normal pulmonary pressure and
PH groups using the mean pulmonary artery pressure (mPAP) values (mPAP≥25mmHg
to define PH) from the RHC data. The PH group was further classified into prePH and
postPH according to the pulmonary capillary wedge pressure (PCWP>15 to define
postPH). The postPH group was further classified into in-proportion (isolated postPH)
and out-of-proportion (combined pre-and postPH) using the diastolic pulmonary
gradient (DPG) since pulmonary vascular resistance (PVR) was only available in a small
number of cases. DPG is calculated as the difference between the diastolic pulmonary
artery pressure and PCWP. DPG is less sensitive to changes in cardiac output and left
atrial pressure. It has become the preferred measurement over the TPG and
recommended in recent guidelines to detect the pulmonary vascular remodelling in PHLHD(1). However, the studies that investigate the prognostic value of DPG have been
showing mixed results (24-26). The TRV was recorded using continuous wave Doppler
while E wave was recorded using pulsed wave Doppler. The septal e’ wave by tissue
Doppler was used to calculate ePLAR for consistency.

3.1. National Echo Database Australia (NEDA)
National echo database Australia (NEDA) is a large, longitudinal, non-interventional
study collecting comprehensive echo measurements and text interpretation information
from multiple participating echocardiography laboratories around Australia, both
prospectively and retrospectively (27). NEDA is headed by 2 principal investigators and
a steering committee of eminent cardiologists and researchers. It is a real-world database
study aiming to take advantage of big data collection as well as increasing sophistication
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of modern echocardiography practice. The linkage of NEDA with health outcome data
such as national death index will provide unique ability to analyse the population data
and investigate valuable echocardiographic markers that predict the risks associated with
multiple cardiovascular pathologies such as pulmonary hypertension, valvular heart
disease and heart failure. Currently, NEDA study has been approved in 20 large
Australian Hospitals and the database is growing. It has collected the echo data from
435,122 individuals to date (28).
The vender-neutral data extraction tool was developed by the team of NEDA engineers
which can be applied to the imported data from individual echo laboratories. The
imported data is then transformed into standardized database using the NEDA data
dictionary, given the differing variable names with each echocardiography vendor. The
NEDA data transfer and transformation process are illustrated in figure 1 and 2 in the
appendix session (page 56).

4. Statistical Analysis

Continuous variables were skewed and are reported as median and interquartile range
(IQR), with statistical significance assessed by Mann Whitney U test. The categorical
variables are reported as number and percentages. Chi-square tests were used to compare
categorical variables.

The accuracy of echocardiography to detect PH by RHC criteria (mPAP³25mmHg) was
calculated using cross tabulation and ROC curve analyses. The sensitivity, specificity
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and predictive values of various ePLAR cut-offs to detect postPH were calculated by
cross tabulation and ROC curve analyses. Correlations of ePLAR to RHC variables
(DPG, TPG and PVR) were also calculated using Pearson’s correlation coefficient.
Binominal logistic regression was used to examine the performance of ePLAR to predict
postPH, in comparison with other echo variables and markers (left ventricular ejection
fraction, Mitral E velocity and age). ROC curve analysis was used to compare the
accuracy of ePLAR and PVRecho. The correlation between components of TPG (mPAP
and PCWP) and ePLAR (TRV and E/e’) were also examined by linear regression.

5. Results

During the study period, 997 RHCs were recorded on a total of 836 patients. Using
identifiers from the RHC database, 887 echos on a total of 732 patients were found
within the NEDA. The databases were merged into a single database for further
analyses. The median time difference between the two procedures was 7 (interquartile
range 1-62) days.

5.1. Agreement between Echo and RHC to diagnose PH

Pulmonary artery systolic pressure (PASP) was recorded in 73% (n=649) of echos. Fifty
four percent (n=476) had pulmonary hypertension by echocardiographic criteria
(PASP³40mmHg). Sixty eight percent of RHC (n=601) had mPAP³25mmHg. The
sensitivity and specificity of echocardiography to detect pulmonary hypertension using
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RHC as gold standard was 82% and 49% (r=0.63, p=<0.001) using the cut-offs of
PASP³40mmHg for echo and mPAP³25mmHg for RHC to define PH.

5.2. ePLAR cohort

The ePLAR could be calculated in 21% (n=184) of patients, of which 32% (n=59) did
not have PH (mPAP<25mmHg). The median ePLAR (IQR) of these cases without PH
was 0.16 (0.11-27) m/s. The breakdown on the ePLAR cohort is illustrated in figure 1.
One hundred and twenty-five cases with PH (mPAP³25mmHg) and measurable ePLAR
were

divided

into

pre-capillary

(PCWP<15mmHg,

n=18)

and

post-capillary

(PCWP³15mmHg, n=105) physiologies. Two RHCs had no recorded PCWP. Despite
similar mPAP, prePH patients had a median ePLAR (IQR) of 0.35 (0.13-0.50) m/s vs
0.17 (0.12-0.23) m/s (P=0.003) for postPH patients. The comparison of demographic,
RHC and echo variables between the two groups is summarized in Table 1. Similar
comparison was also made for isolated postPH and combined pre-and post-capillary PH
patients (table 2). The ePLAR cut-offs value of <0.25m/s and <0.28m/s had positive
predictive values (PPV) of 93% and 94% respectively for postPH (figure 2), with
reasonable sensitivity and specificity (78% and 67% for <0.25m/s and 83% and 67% for
<0.28m/s) (Appendix 3).

The correlations between the ePLAR and DPG, TPG and PVR were also examined.
PVR was only calculable in 47 out of 184 cases in the ePLAR cohort due to cardiac
output (CO) being infrequently measured in our database. In this subgroup, Pearson’s
correlation coefficients (r) of ePLAR to DPG, TPG and PVR were 0.19 (p=0.097), 0.02
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(p=0.44) and -0.05 (p=0.37) respectively (Appendix 3). Pearson’s correlation coefficient
(r) between TRV and mPAP was modest at 0.58 (p value = <0.001) while r between the
PCWP and E/e’ was weak at 0.25 (p = < 0.001). Binominal logistic regression was
performed to test the impact of the ePLAR, left ventricular EF, mitral E velocity and age
on the likelihood of individuals having postPH. Increasing ePLAR value, EF and age
were associated with reduction in likelihood of postPH while increasing mitral E
velocity was associated with higher likelihood of postPH. ePLAR performed better than
any other covariates (regression coefficient=-6.46, p=0.017) (Appendix 3).

5.3. ePLAR against PVRecho in differentiating prePH and post PH
To compare ePLAR against other non-invasive echo markers used to separate postPH
from prePH, we applied two commonly used formulae to our data. PVR was calculable
using Abbas’ formulae (17, 18) in 24% (n=209) of the combined echo and RHC cohort.
Of these individuals 146 had a RHC that was consistent with PH (mPAP≥25mmHg).
The mean PVRecho value for 33 cases with prePH was similar to that of 113 cases with
postPH: 3.7+/-2 WU vs 3.9+/-2 WU (p=0.67). ROC curves confirm that ePLAR (both
cut-off values of 0.25 and 0.28) is a better discriminator of postPH than the Abbas
PVRecho formulae (using a cut-off <3 to define postPH), figure 3.

6. Discussion
The current study confirms that the ePLAR is a useful non-invasive method to help
differentiate prePH from postPH. Patients with postPH who have lower TPG and DPG
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were found to have low ePLAR values, indicating the usefulness of ePLAR in
highlighting patients with PH-LHD (Group 2 PH). Certainly, in the current study the
clear majority of patients with PH had evidence of an isolated post-capillary mechanism
and in these patients, RHCs might have been avoided if there was a well validated noninvasive surrogate to RHC – such as ePLAR. On the other hand, PH patients with higher
ePLAR have prePH physiology (higher TPG and DPG) and they may require further
testing including RHC to further clarify the underlying pathologies.

The main strength of ePLAR is its simplicity. Its calculation only requires two Doppler
variables (TRV and E/e’) which are easily measurable. It should not take extra time or
effort for one to measure ePLAR while performing a routine echocardiography. Instead
of using pulmonary artery systolic pressure estimation which requires the estimation of
right atrial pressure which can be a further source of error, the formula uses TRV on its
own. The correlation between E/e’ ratio and left atrial pressure has also been well
validated in previous studies, even in the presence of atrial fibrillation(22, 29, 30). In
theory, the ratio between the pulmonary pressure represented by TRV to left atrial
pressure represented by E/e’ should correlate well with transpulmonary gradient (TPG)
which is calculated as the mean pulmonary artery pressure minus the pulmonary
capillary wedge pressure (PCWP) representing the left atrial pressure. Although the
calculation of ePLAR does not include a measurement that represents blood flow or
cardiac output, it performed better than the commonly used PVRecho formulae in
differentiating two major PH physiologies.
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6.1. Prior Studies
Previous investigators had examined a variety of non-invasive surrogate markers of PVR
(17, 18, 23) to differentiate the underlying aetiologies of PH. Some of these markers
have been validated in subsequent studies and proved to be useful; however, most of
these studies had small sample sizes. A combined clinical and echo risk scoring system
was also proposed to identify PH-LHD and reduce the number of unnecessary RHCs
(31). In its foundation study involving 133 PH patients who had RHC, ePLAR was
found to have good accuracy in differentiating prePH and postPH (19).

6.2. Strengths and limitations
The data for this study were extracted automatically from large databases, minimising
the risk of any human error. In addition, our study has the advantage of testing the
usefulness of the ePLAR in a ‘real-world’ dataset. Our study is also larger than previous
studies despite the low percentage of patients with calculable ePLAR. It does, however,
also have some limitations. The most important of these is that the RHC and echo data
were not acquired simultaneously. This may explain the modest correlation between the
two modalities in terms of defining PH, though previous data have shown similar
associations even during simultaneous measurements (32). Although ePLAR has
provided a good discriminatory power between two PH physiologies, its accuracy needs
further improvement. In the current study, the optimal ePLAR cut-off of <0.28 gives
sensitivity of 83% which means there are still considerable chance of having false
negative test results. To be clinically useful as a non-invasive tool, ePLAR should have
very high sensitivity and low false negative rate, given the dire consequence of missing
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PAH patients which has proven specific therapy.
Another inherent weakness of the ePLAR, as well as the PVRecho formulae, is that both
require measurement of TRV which cannot be accurately estimated in some patients.
The TRV was not available in 45% of echos in our study in keeping with previous data
suggesting that approximately 1 in 3 echos do not have evaluable TR velocities (2).
Although we lacked clinical data in our study, the primary purpose was to compare
invasive and non-invasive methods of estimating pulmonary vascular resistance rather
than diagnosing the final cause of pulmonary hypertension. Moreover, cardiac output
was infrequently measured during RHC and subsequently PVRRHC was not calculable in
most of the patients in the database. Only 4 % (n=35) of cases have both measurable
PVRecho and PVRRHC. Furthermore, some components of ePLAR and PVRecho were
either not routinely measured or recorded in our database; contrary to our expectation.
Despite these limitations, ePLAR appears to be a useful non-invasive tool to help
differentiate prePH from postPH. A prospective study, involving simultaneous
measurements of echo and RHC parameters, in a group of patients with different
haemodynamic classes of PH, is needed to further investigate the performance of
ePLAR. This will also increase the percentages of studied subject with calculable
ePLAR.

7. Conclusions
We have investigated the performance and feasibility of ePLAR in a large single centre,
real world database containing RHC and echo data. Although ePLAR was only
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calculable in 21% of the cohort, it provided good discriminatory power between pre-and
postPH, and was superior in this respect to previous echocardiographic formulae.
Further work is required to validate the discriminatory potential of the ePLAR
prospectively and to clarify its ability to identify those individuals who will benefit from
RHC and potentially from disease specific therapy.
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Figure 1. ePLAR flow chart

401 echoes had no
TRV recorded.
594 echoes had no
E/e’ recorded
Only 184 echoes
had both TRV and
E/e’
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Table 1. Comparison of demographic, RHC and echo variables between the preand post-capillary pulmonary hypertension patients in whom ePLAR can be
calculated.
Variable

Pre-capillary PH

Post-capillary PH

Median (IQR)
70 (54-86)
61%
23 (21-27)

N

Age (years)
Female (percentage)
BMI (kg/m2)

N
18
18
16

Mean pulmonary
artery pressure
(mmHg)
Pulmonary capillary
wedge pressure
(mmHg)
Diastolic Pulmonary
Gradient (mmHg)
Transpulmonary
gradient (mmHg)
Cardiac output
(L/min)
Pulmonary vascular
resistant (WU)
Ejection Fraction (%)

18

P value

105
105
67

Median (IQR)
71 (51-84)
44%
26 (24-31)

0.983
0.17#
0.014

35 (28-48)

105

36 (30-43)

0.912

18

13 (9-14)

105

22 (18-29)

0.000

18

10 (4-17)

105

1 (-3-4)

0.000

18

21 (16-37)

105

11 (8-17)

0.000

4

4.6 (4.3-5.4)

24

4.0 (3.1-4.9)

0.211

4

6.4 (4.8-7.1)

24

8.6 (6.6-10.5)

0.057

18

68 (61-73)

100

51 (34-64)

0.000

Mitral E:A

16

0.9 (0.7-1.2)

79

1.7 (0.8-2.9)

0.011

LA volume (indexed)
(cm3)
Tricuspid
Regurgitation
Velocity (m/s)
Mitral E/e'
ePLAR (m/s)

3

29 (27-.)

31

57 (43-71)

0.008

18

3.5 (2.9-4.2)

105

3.2 (2.8-3.5)

0.035

18
18

10 (9-22)
0.35 (0.13-0.50)

105
105

19 (14-27)
0.17 (0.12-0.23)

0.004
0.003

Abbas’ original
PVRecho, (WU)
Abbas’ sharpened
PVRecho (WU)

14

2.6 (1.9-3.8)

52

0.147

14

5.4 (2.9-7.7)

52

3.2 (2.5-4.9)
(n=52)
4.9 (3.5-8.8)
(n=52)

0.556

# p value obtained by Pearson chi-square test
IQR= interquartile range, ePLAR= echocardiographic pulmonary to left atrial ratio, N=
number of patients
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Table 2. Comparison of demographic, RHC and echo variables between the
isolated post capillary and combined pre-and post-capillary pulmonary
hypertension patients in whom ePLAR can be calculated.
Variable
Age (years)
BMI (kg/m2)
Mean pulmonary
artery pressure
(mmHg)
Pulmonary capillary
wedge pressure
(mmHg)
Diastolic Pulmonary
Gradient (mmHg)
Transpulmonary
gradient (mmHg)
Cardiac output
(L/min)
Pulmonary vascular
resistant (WU)
Ejection Fraction (%)
Mitral E:A
LA volume (indexed)
(cm3)
Tricuspid
Regurgitation
Velocity (m/s)
Mitral E/e'
ePLAR (m/s)
Abbas’ original
PVRecho (WU)
Abbas’ sharpened
PVRecho (WU)

Isolated postPH
N
Median (IQR)
86
72 (51-84)
56
26 (23-31)
86
33 (29-41)

Combined pre-and postPH
N
Median (IQR)
19
64 (51-83)
11
30 (26-31)
19
42 (37-49)

P value

86

24 (19-29)

19

18 (17-22)

0.001

86

0 (-4-3)

19

10 (9-16)

0.000

86

10 (7-13)

19

22 (17-31)

0.000

21

4.0 (3.1-5)

3

4.5 (3.1-.)

0.793

21

8.3 (6.3-10.2)

3

10.2 (7.1-.)

0.359

81
61
27

50 (30-63)
1.7 (0.9-3)
57 (45-71)

19
18
4

58 (36-69)
1.1 (0.7-2.6)
44 (32-66)

0.098
0.183
0.239

86

3.1 (2.7-3.4)

19

3.8 (3.1-4.1)

0.009

86
86
41

19 (15-28)
0.16 (0.11-0.21)
3.0 (2.4-5.2)

19
19
11

19 (13-22)
0.19 (0.15-0.28)
3.9 (3.1-4.6)

0.312
0.042
0.226

41

4.3 (3.4-8.7)

11

7.1 (4.1-9.1)

0.165

0.641
0.134
0.000

IQR= interquartile range, ePLAR= echocardiographic pulmonary to left atrial ratio, N=
number of patients
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Figure 2. Scatter plot showing distribution of ePLAR values in two major
physiology groups: pre-capillary PH and post-capillary PH, with the table showing
sensitivity, specificity and predictive values of each ePLAR cut-off to predict
postPH

78%

PPV= positive predictive value, NPV=negative predictive value
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Figure 3. ROC analysis on 2 different ePLAR cut-offs compared with PVRecho
formulae by Abbas et al. to detect post capillary PH
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Chapter 4. Summary, Key Findings, Recommendations and Future Directions
4.1. Summary
This thesis is written to contribute to the body of knowledge in managing patients with
PH which is a serious and common health problem (2). In the chapter 2, the
pathophysiology of PH, its classification and underlying aetiologies were described in
detail. Among the 5 PH groups as per the 2013 Nice Classification(10), group 1 or
pulmonary arterial hypertension (PAH) has the specific advanced therapy targeting at
pulmonary vasculature. The prognosis of PAH patients has much improved because of
this advanced therapy. However, there is no evidence that the advanced therapy is
beneficial for PH patients due to other causes such as left heart (group 2) and lung
diseases (group 3) (1). Multiple studies have suggested that PH-LHD (pulmonary
hypertension due to left heart disease) is the most common cause (2, 13). Systolic or
diastolic left ventricular failure and left sided valvular diseases can lead to PH-LHD.
Owing to the aging population and higher prevalence of risk factors such as diabetes and
hypertension in the general population, the prevalence of HFpEF has increased
dramatically. PH due to HFpEF is a particularly challenging diagnosis as the left
ventricular diastolic dysfunction may not be easily recognised. It is estimated that
around 50% of HFpEF patients will develop PH (33). In a cross-sectional survey of 2042
randomly selected residents older than 45 years in Minnesota between 1997 to 2000,
20.8%,6.6% and 0.7% of population had mild, moderate and severe diastolic
dysfunction (34). Even in the absence of clinical syndrome of congestive heart failure,
the moderate and severe diastolic dysfunction were associated with significant increase
in all-cause mortality in this study.
The physiology of pulmonary circulation and the concept of PVR were also explained in
chapter 2. The PVR is an important parameter which can determine the underlying
pathophysiology of PH and RHC is the gold standard method to measure it. It is
calculated as transpulmonary gradient (TPG) divided by the cardiac output (CO). TPG is
the pressure difference between the mean pulmonary arterial pressure and left atrial
pressure represented by PCWP (pulmonary capillary wedge pressure). The importance
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of differentiating prePH (pre-capillary PH) vs postPH (post-capillary PH) by measuring
PCWP and PVR using right heart catheterisation (RHC) was discussed. The risks and
limitations of RHC (right heart catheterisation) were also discussed. I also described
how important it is for PH patients to get correct diagnosis early in their disease process
for better outcomes. The prePH patients have higher TPG and PVR (PVR>3WU) while
postPH patients have elevated left heart pressure (PCWP) and low TPG and PVR. The
PAH (pulmonary arterial hypertension) is a relatively rare form of PH where the specific
advanced therapy is indicated. The advanced therapy includes vasodilators targeting the
pulmonary vasculature such as endothelin receptor antagonists (e.g. mecitentan,
bosentan and ambrisentan) and phosphodiesterase type 5 inhibitors (e.g. sildenafil and
tadalafil). The diagnosis of PAH requires the presence of prePH which is defined as
PCWP ≤ 15mmHg and PVR > 3WU in the absence of other causes of prePH (e.g. PH
due to lung diseases, CTEPH (chronic thromboembolic PH) or other rare diseases (35).
The postPH is mainly secondary to left heart diseases such as systolic and diastolic left
ventricular failure and left sided valvular heart diseases (aortic and mitral). The
management of postPH should be focused on correcting the underlying left heart
diseases and advanced therapy or PAH approved therapy in not indicated.
It is not only impossible to do RHC in all PH patients but also such an approach is not
necessary. A reliable echocardiographic marker which can differentiate different
physiologies of PH is needed to improve PH evaluation. This will reduce the number of
unnecessary RHC and will improve the utilisation of available resources by better
selection of patients who require invasive tests. Researchers worldwide have been
investigating for an ideal non-invasive way of estimating PVR with varying success as
we described in the chapter 2. The original PVRecho formula was described by Abbas et
al in 2003 and it has been modified and improved by multiple researchers(36). The
ePLAR (echocardiographic pulmonary to left atrial ratio) was introduced as a noninvasive surrogate of TPG (transpulmonary gradient) and its ability to differentiate
between prePH and postPH was demonstrated in its pilot study involving 133 patients
with PH(19). There were also studies investigating combined clinical and non-invasive
investigations to identify left heart diseases among patients suspicious for PAH(31).
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4.2. Key findings
Chapter 3 describes the current research in detail. This is a large real-world, single
centre retrospective study involving 887 pairs of echos and RHCs. The data were
automatically extracted from 2 data-bases (echo and RHC) minimising the humans error
of manual data collection. The main finding was that the ePLAR provided good
discriminatory power between prePH and postPH when compared with the current gold
standard, RHC. There was a statistically significant difference in median ePLAR (IQR)
values between prePH and postPH patients (0.35 (0.13-0.50) m/s vs 0.17 (0.12-0.23) m/s
(P=0.003). It also performed better than previously published PVRecho formulae(17, 18)
in predicting the increased left atrial pressure (PCWP). The binomial logistic regression
showed that ePLAR performed better than ejection fraction, age and mitral E velocity in
predicting patients with postPH. The diastolic pulmonary gradient (DPG) has emerged
as preferred marker to differentiate isolated post-capillary PH and combined pre-and
post-capillary PH (1, 24). Therefore, DPG was used in our study to differentiate between
the two groups in our study. The study also confirmed that the isolated post-capillary PH
is the dominant physiology among patients who presented for RHC. In general, these
patients will not benefit from the vasodilator therapy and RHC may not be necessary
unless the patients were being worked up for heart transplant.
4.3. Recommendations and Future Directions
I do not believe that ePLAR or any other non-invasive surrogates of PVR will replace
the role of RHC completely. RHC will still be the gold standard to confirm the diagnosis
and to exclude significant elevation of left heart pressure (PCWP>15mmHg) in patients
with PAH. However, in majority of PH patients, ePLAR may be a useful adjunct tool to
other echo parameters in selecting appropriate patients who require invasive tests to
further clarify the diagnosis. Development and validation of such a marker will be very
useful in PH management and will lead to better resource management and early
diagnosis for many patients.
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Being a retrospective study, the study had inherent weaknesses such as incomplete data
set and limited clinical information. These weaknesses limited our ability to investigate
the accuracy of ePLAR to estimate the invasive PVR. Non-simultaneous performance of
the RHC and echo for studied patients is also another limitation as the pressure
measurements by both tests are dependent upon multiple factors such as fluid volume
status and heart rate which are very dynamic in nature. A prospective study involving
simultaneous echo and RHC in PH patients with different underlying aetiologies would
be an ideal future study. A similar large retrospective study which includes
comprehensive clinical information will also be a very useful study. There is also a
possibility of further improving the ePLAR formula by including a surrogate for the
cardiac output such as TVIRVOT (time velocity integral of blood flow through the right
ventricular outflow tract) and testing it in the current data set or in a future prospective
study.
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Appendices
1.Conference Presentations
i. Performance of a novel echocardiographic marker against right heart
catheterization in identifying pulmonary hypertension due to left heart disease
(mini-oral presentation at CSANZ 2017)
Pyi Naing1, Gregory Scalia2, Graham S. Hillis3, Geoff Strange1,4, David Playford1
1

University of Notre Dame Australia, Fremantle, Western Australia,2 Prince Charles

Hospital, Queensland,
3

Royal Perth Hospital, Western Australia, 4Royal Prince Alfred Hospital, Sydney

Hypothesis/Aims
•

Right heart catheterization (RHC) is the current gold standard for evaluation of
patients with pulmonary hypertension (PH); however, it is invasive, not suitable
for all patients, and has associated risk.

•

We aimed to investigate the feasibility and performance of echocardiographic
Pulmonary to Left Atrial Ratio (ePLAR) to differentiate between the two major
physiologies (pre-capillary PH and post-capillary PH) in a large real-world
database containing RHCs and echocardiograms.

•

ePLAR = TRV/E/e’
– ePLAR = Echocardiographic Pulmonary to Left Atrial Ratio
– TRV = Tricuspid Regurgitation Velocity (m/s)
– E/e’ = Ratio of early mitral inflow velocity to early basal septal
relaxation velocity using tissue Doppler

Methods
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•

A retrospective cohort study was conducted at the Royal Perth Hospital, a
tertiary referral centre for PH patients.

•

RHC data from hospital database and echo data from National Echo Database
Australia (NEDA) were collected and merged.

Results
Variables

Pre-capillary PH

Post-capillary PH

p

(n=18)

(n=105)

values

67 (20) years

67 (20) years

0.99*

Females (%)

61%

44%

0.17#

mPAP,

37 (10) mmHg

37 (9) mmHg

0.94*

12 (3) mmHg

24 (7) mmHg

<0.001*

11 (8) mmHg

1 (7) mmHg

<0.001*

64 (14) % (n=18)

48 (20) % (n=100)

<0.001*

3.6 (0.7) m/s

3.2 (0.6) m/s

0.01*

Mean age
(SD)

mean (SD)
PCWP,
mean (SD)
DPG, mean
(SD)
Ejection
Fraction,
mean (SD)
TRV, mean
(SD)
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14 (7)

20 (9)

0.004*

0.35 (0.2) m/s

0.19 (0.1) m/s

0.004*

Abbas

3.24 (2.2) WU

3.92 (2) WU (n=52)

0.29*

PVRecho

(n=14)

6.49 (3.89) WU (n=52)

0.9*

Mitral E/e’,
mean (SD)
ePLAR,
mean (SD)

(original),
mean (SD)
Abbas

6.66 (5.9) WU

PVRecho

(n=14)

(sharpened),
mean (SD)

Summary & Conclusions
•

ePLAR provides good discriminatory power between pre-and post-capillary PH
(0.35±0.2m/s vs 0.19±0.1m/s, P=0.004).

•

ePLAR performs superiorly to non-invasive PVR assessment in predicting
elevated wedge pressures.

•

ePLAR cut-off of <0.28m/s provided the excellent positive predictive value of
94% for post capillary PH while maintaining good sensitivity of 83% and
specificity of 67%. It also provided the best AUC on the ROC curve analysis.
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ii. NEDA PH-LHD predictive model: Validation of diastolic markers of pulmonary
hypertension with Right Heart Catheterisation (Oral Presentation at CSANZ 2017)
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The above abstract presented at the CSANZ ASM 2017 used our data to validate the
NEDA PH-LHD prediction formula. Our data formed important part of the development
of this formula as right heart catheterisation remains the gold standard in PH
evaluation. This abstract fulfilled the secondary objective of the thesis: identification of
echo markers of increased left heart pressure in the setting of PH, i.e., PH-LHD.
iii. Poster Presentation at ASE 2018, June 2018 in Nashville, USA

Differentiating Pre-Capillary and Post-Capillary Pulmonary Hypertension by Doppler Echocardiography in a Large Real-world Database
Pyi Naing1, Graham S. Hillis2, Gregory Scalia3, Geoff Strange1, Jim Codde1, David Playford1.
1University of Notre Dame, Fremantle, WA, Australia; 2University of Western Australia, Perth, WA, Australia; 3University of Queensland, Brisbane, Australia

Background: Pulmonary hypertension (PH) is common, dangerous
and has multiple causes. Vasodilator therapy has significantly
improved the prognosis of patients with pulmonary arterial
hypertension (PAH), but the diagnosis can be challenging, requiring
right heart catheterisation (RHC). Differentiating pre-capillary PH
(prePH) and post-capillary PH (postPH) and measuring pulmonary
vascular resistance (PVR) are key steps for diagnosing PAH. A novel
echocardiographic parameter, the pulmonary to left atrial ratio
(ePLAR), which is derived from the tricuspid regurgitation velocity
(TRV) divided by the ratio between the early diastolic filling velocity
and the early mitral annulus velocity (E/e’), i.e., ePLAR=TRV/E/e’, has
been described as a surrogate for RHC. This retrospective cohort
study tests the ability of ePLAR to differentiate prePH and postPH, in
a large real world database.
The figure depicting how ePLAR is calculated
using the Doppler echocardiography

Methods: The data from all RHC performed within 5 years’ period
(January 2010 to February 2015) was extracted from the Royal Perth
Hospital’s database. The closest corresponding echocardiograms
(echos) were searched in the national echo database Australia (NEDA)
using the identifiers from RHC data.

Results: 887 pairs of echos and RHCs were merged and analysed in our
study. The median time difference between RHC and echocardiography
was 7 (IQR 1-62) days. The ePLAR was calculable in 184 cases (21%).
Median (IQR) ePLAR values were significantly different between prePH and
postPH groups: 0.35 (0.13-0.50) m/s vs 0.17 (0.12-0.23) m/s (P=0.003),
despite both groups having similar mean pulmonary artery pressures. The
optimal ePLAR cut-off of 0.28m/s had a positive predictive value of 94%
for postPH, with sensitivity of 83% and specificity of 67%.
Variables

Age (years)
Female
(percentage)
mPAP (mmHg)
PCWP (mmHg)
DPG (mmHg)
TPG (mmHg)
Cardiac output
(L/min)
PVR (WU)
Ejection Fraction
(%)
LAVI (cm3)
TRVmax(m/s)
Mitral E/e'
ePLAR (m/s)

Pre-capillary PH

Post-capillary PH

P value

N
18
18

Median (IQR)
70 (54-86)
61%

N
Median (IQR)
105 71 (51-84)
105 44%

0.983
0.17

18
18
18
18
4

35 (28-48)
13 (9-14)
10 (4-17)
21 (16-37)
4.6 (4.3-5.4)

105
105
105
105
24

0.912
0.000
0.000
0.000
0.211

4
18

6.4 (4.8-7.1)
68 (61-73)

24 8.6 (6.6-10.5)
100 51 (34-64)

0.057
0.000

Conclusions: ePLAR helps to discriminate postPH from prePH and may be
useful in evaluating these patients.

3
18
18
18

29 (27-N/A)
3.5 (2.9-4.2)
10 (9-22)
0.35 (0.13-0.50)

31
105
105
105

0.008
0.035
0.004
0.003

Reference: Scalia GM, Scalia IG, Kierle R, Beaumont R, Cross DB, Feenstra J,
et al. ePLAR The echocardiographic Pulmonary to Left Atrial Ratio: A novel
non-invasive parameter to differentiate pre-capillary and post- capillary
pulmonary hypertension. Int J Cardiol 2016;212:379–86

36 (30-43)
22 (18-29)
1 (-3-4)
11 (8-17)
4.0 (3.1-4.9)

57 (43-71)
3.2 (2.8-3.5)
19 (14-27)
0.17 (0.12-0.23)

The table comparing demographic, RHC and echo variables between the pre-and
post-capillary pulmonary hypertension patients in whom ePLAR can be calculated.
mPAP= mean pulmonary artery pressure; PCWP= pulmonary capillary wedge
pressure; PVR= Pulmonary Vascular Resistance; DPG= diastolic pulmonary gradient;
TPG= transpulmonary gradient, LAVI= left atrial volume indexed

Graphical comparison of distribution of median ePLAR values, IQR, highest and
lowest values and outliers between the two PH groups
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2. NEDA Data Transfer and Transformation Process

68

3. Statistical Calculations
2x2 tables showing specificity, sensitivity and predictive values of different ePLAR
cut-offs to predict postPH
prePH
12
6

ePLAR>0.25
ePLAR<0.25

postPH
23
82

Sensitivity = 82/ (82+23) = 78%
Specificity = 12/ (12+6) = 67%
Positive Predictive Value = 82/ (82+6) = 93%
Negative Predictive Value = 12/ (12+23) = 40%
prePH
12
6

ePLAR>0.28
ePLAR<0.28

postPH
18
87

Sensitivity = 87/ (87+18) =83%
Specificity = 12/ (12+6) = 67%
Positive Predictive Value = 87/ (87+6) = 94%
Negative Predictive Value = 12/ (12+18) = 34%

high ePLAR
low ePLAR

prePH
TN
FP

sensitivity
specificity
PPV
NPV

TP/(TP+FN)
TN/(TN+FP)
TP/(TP+FP)
TN/(TN+FN)

postPH
FN
TP
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Pearson Correlation of ePLAR to DPG, TPG and PVR

Binominal Logistic Regression of ePLAR and other variables that predict
postPH
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